Vera Therapeutics, Inc. Restructuring Charges
Vera Therapeutics, Inc. (VERA) reported Restructuring Charges of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2022-03-28
- Vera Therapeutics, Inc. restructuring charges for the quarter ending 2021-12-31 was -$116.00K, a 107.34% decline year-over-year.
- Vera Therapeutics, Inc. restructuring charges for the quarter ending 2021-09-30 was $31.00K, a 97.81% decline year-over-year.
- Vera Therapeutics, Inc. restructuring charges for the quarter ending 2021-06-30 was $50.00K.
- Vera Therapeutics, Inc. restructuring charges for the quarter ending 2021-03-31 was $35.00K.
- Vera Therapeutics, Inc. restructuring charges for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Vera Therapeutics, Inc. restructuring charges for fiscal 2020 was $3.00M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$116.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$85.00K derived: sum of 2 quarters · filed 2022-03-28 | -$35.00K derived: sum of 3 quarters · filed 2022-03-28 | $0.00 10-K · filed 2022-03-28 |
| 2021-09-30 | $31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $81.00K derived: sum of 2 quarters · filed 2021-11-10 | $116.00K 10-Q · filed 2021-11-10 | $1.70M derived: sum of 4 quarters · filed 2022-03-28 |
| 2021-06-30 | $50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $85.00K 10-Q · filed 2021-08-16 | $1.67M derived: sum of 3 quarters · filed 2022-03-28 | $3.08M derived: sum of 4 quarters · filed 2022-03-28 |
| 2021-03-31 | $35.00K 10-Q · filed 2021-06-24 | $1.61M derived: sum of 2 quarters · filed 2022-03-28 | $3.03M derived: sum of 3 quarters · filed 2022-03-28 | |
| 2020-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $3.00M derived: sum of 2 quarters · filed 2022-03-28 | $3.00M 10-K · filed 2022-03-28 | |
| 2020-09-30 | $1.42M 10-Q · filed 2021-11-10 | $1.42M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |